Concentration and Glycoform of Rituximab in Plasma of Patients with B Cell Non-Hodgkin’s Lymphoma
-
- Otani, Yuki
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- 米澤, 淳
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital･Graduate School of Pharmaceutical Sciences, Kyoto University
-
- Mori, Mayuko
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital･Graduate School of Pharmaceutical Sciences, Kyoto University
-
- 北野, 俊行
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University･Department of HematologyKitano Hospital, Osaka
-
- Isomoto, Yui
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- Masui, Sho
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital･Graduate School of Pharmaceutical Sciences, Kyoto University
-
- 津田, 真弘
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital･Graduate School of Pharmaceutical Sciences, Kyoto University
-
- Imai, Satoshi
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- Ikemi, Yasuaki
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- Denda, Masaya
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital･Graduate School of Pharmaceutical Sciences, Kyoto University
-
- Sato, Yuki
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- 中川, 俊作
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- 大村, 友博
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- Nakagawa, Takayuki
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- 矢野, 育子
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital･Graduate School of Pharmaceutical Sciences, Kyoto University･Department of Pharmacy, Kobe University Hospital
-
- Hayakari, Makoto
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- 髙折, 晃史
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University
-
- 松原, 和夫
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
書誌事項
- 公開日
- 2019-06
- 資源種別
- journal article
- 権利情報
-
- This is a post-peer-review, pre-copyedit version of an article published in Pharmaceutical Research. The final authenticated version is available online at: http://dx.doi.org/10.1007/s11095-019-2624-5.
- The full-text file will be made open to the public on 15 April 2020 in accordance with publisher's 'Terms and Conditions for Self-Archiving'.
- This is not the published version. Please cite only the published version.
- この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。
- DOI
-
- 10.1007/s11095-019-2624-5
- 公開者
- Springer Nature
この論文をさがす
説明
Purpose: Therapeutic antibodies have heterogeneities in their structures, although its structural alteration in the body is unclear. Here, we analyzed the change of amino acid modifications and carbohydrate chains of rituximab after administration to patients. Methods: Twenty B cell non-Hodgkin’s lymphoma patients who were treated with rituximab for the first time or after more than one year’s abstinence were recruited. Structural analysis of rituximab was carried out at 1 h after administration and at the trough by using liquid chromatography/time-of-flight-mass spectrometry. Plasma rituximab concentration and pharmacodynamic markers were also determined. Results: Of recruited twenty, 3 patients exhibited rapid rituximab clearance. Nine types of carbohydrate chains were detected in rituximab isolated from the blood. The composition ratios in some glycoforms were significantly different between at 1 h after administration and at the trough, although consisted amino acids remained unchanged. The patients with high clearance showed extensive alterations of glycoform composition ratios. However, pharmacodynamics makers were not different. Conclusion: Inter-individual variations in plasma concentrations of rituximab were found in some B-NHL patients. We could analyze a change in glycoforms of rituximab in the patients, and this finding may affect the pharmacokinetics of rituximab.
収録刊行物
-
- Pharmaceutical research
-
Pharmaceutical research 36 82-, 2019-06
Springer Nature
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1050845763182203520
-
- NII論文ID
- 120006624113
-
- NII書誌ID
- AA10632083
-
- ISSN
- 1573904X
- 07248741
-
- HANDLE
- 2433/241257
-
- PubMed
- 30989405
-
- 本文言語コード
- en
-
- 資料種別
- journal article
-
- データソース種別
-
- IRDB
- Crossref
- CiNii Articles
- KAKEN
- OpenAIRE
